多価ワクチンの世界市場レポート 2025年

多価ワクチン市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は9.7％で、133億2,000万米ドルに成長します。予測期間の成長は、感染症罹患率の上昇、高齢者人口の増加、政府および民間セクターの投資の増加、ワクチンの安全性と有効性への注目の高まり、治療用ワクチンへの注目の高まりに起因すると考えられます。予測期間における主な動向としては、混合ワクチンの重視、デジタルヘルス技術の統合、mRNA技術の開発、個別化ワクチンの開発、研究活動の増加などが挙げられます。

感染症の流行の増加は、近い将来、多価ワクチン市場の成長を大きく牽引すると予測されます。感染症は、細菌、ウイルス、真菌、寄生虫などの病原体によって引き起こされ、直接接触したり、汚染された表面、空気、水を通して感染し、重症度は軽度から重度までさまざまです。世界の旅行環境は、これらの疾病の急速な蔓延を促し、病原体が容易に国境を越えて新たな集団に感染することを可能にしています。多価ワクチンは、1回の接種で複数の病原体株を標的とすることで、感染症に対する幅広い防御を提供し、複数回の予防注射の必要性を減らします。このような包括的な予防接種により、集団免疫が強化され、疾病の流行が減少するため、公衆衛生上の成果が向上します。例えば、TravelHealthProが2024年4月に発表した報告書によると、英国では2023年に2,004件のマラリア症例が報告され、2022年の輸入症例1,369件から増加しました。その結果、感染症の発生件数の増加が多価ワクチン市場の成長を促進する重要な要因となっています。

多価ワクチン分野の主要企業は、1回の投与で幅広い予防効果をもたらし、公衆衛生全体の成果を高めるため、先進的な5価ワクチンの開発に注力しています。5価ワクチンは、5つの異なる病原体または菌株を防御するよう特別に設計されています。このように防御を統合することで、予防接種スケジュールが簡素化され、全体的なワクチン接種率が向上します。例えば、2023年12月、インドのバイオテクノロジー企業であるPanacea Biotec Ltd.は、世界初の完全液状ワクチンであるEasyFourPolを発表しました。この革新的なワクチンは、ジフテリア、破傷風、百日咳、ポリオ、B型インフルエンザ菌による侵襲性感染症を含む5つの重篤な疾患を予防します。単一抗原ワクチンと同等の予防効果を発揮し、小児に必要な診療回数を減らし、予防接種費用全体を削減します。さらに、ワクチン接種の効率を高め、バイアル・注射器・包装の必要性を減らすことで環境への影響を最小限に抑えます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界多価ワクチンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の多価ワクチン市場：成長率分析
• 世界の多価ワクチン市場の実績：規模と成長, 2019-2024
• 世界の多価ワクチン市場の予測：規模と成長, 2024-2029, 2034F
• 世界多価ワクチン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の多価ワクチン市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 結合ワクチン
• 不活化ワクチンとサブユニットワクチン
• 生弱毒化ワクチン
• トキソイドワクチン
• 組み換えワクチン
• 世界の多価ワクチン市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• インフルエンザ
• 肺炎
• 肝炎
• 髄膜炎
• ロタウイルス
• 世界の多価ワクチン市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• 世界の多価ワクチン市場：年齢層別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小児科
• 大人
• 老年医学
• 世界の多価ワクチン市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の多価ワクチン市場結合ワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 多糖類結合ワクチン
• タンパク質結合ワクチン
• 世界の多価ワクチン市場不活化ワクチンとサブユニットワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 不活化全ウイルスワクチン
• サブユニットタンパク質ワクチン
• ウイルス様粒子ワクチン
• 世界の多価ワクチン市場生弱毒化ワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生弱毒化細菌ワクチン
• 生弱毒化ウイルスワクチン
• 世界の多価ワクチン市場トキソイドワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジフテリアトキソイドワクチン
• 破傷風トキソイドワクチン
• 世界の多価ワクチン市場、組換えワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 組み換えタンパク質ワクチン
• 組み換えDNAワクチン

第7章 地域別・国別分析

• 世界の多価ワクチン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の多価ワクチン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 多価ワクチン市場：競合情勢
• 多価ワクチン市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• GlaxoSmithKline plc
• Boehringer Ingelheim International GmbH
• Moderna Inc.
• BioNTech SE
• Zydus Lifesciences Limited
• CSL Seqirus
• Sinovac Biotech Ltd.
• GC Biopharma corp.
• Emergent BioSolutions Inc.
• Serum Institute of India Pvt. Ltd.
• Indian Immunologicals Ltd.
• Bavarian Nordic
• Panacea Biotec Ltd.
• WestVac Biopharma Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 多価ワクチン市場2029：新たな機会を提供する国
• 多価ワクチン市場2029：新たな機会を提供するセグメント
• 多価ワクチン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Multivalent vaccines are strategically formulated to provide protection against multiple strains or types of a single pathogen, or against several distinct pathogens, within a single administration. By incorporating antigens from various strains or diseases, these vaccines facilitate the development of immunity against multiple targets simultaneously, thereby delivering broader protection than monovalent vaccines, which focus exclusively on a single strain or pathogen.

The primary categories of multivalent vaccines include conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, toxoid vaccines, and recombinant vaccines. Conjugate vaccines enhance immune recognition and efficacy by linking a weaker antigen to a stronger one, which is particularly beneficial for combating bacterial diseases. These vaccines are applicable for a range of diseases, including influenza, pneumonia, hepatitis, meningitis, and rotavirus, and can be administered via various routes, such as oral and injectable methods. They are designed for a diverse demographic, encompassing pediatric, adult, and geriatric populations, and are distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The multivalent vaccines market research report is one of a series of new reports from The Business Research Company that provides multivalent vaccines market statistics, including multivalent vaccines industry global market size, regional shares, competitors with a multivalent vaccines market share, detailed multivalent vaccines market segments, market trends, and opportunities, and any further data you may need to thrive in the multivalent vaccines industry. These multivalent vaccines market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The multivalent vaccines market size has grown strongly in recent years. It will grow from $8.37 billion in 2024 to $9.2 billion in 2025 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to rising public awareness for vaccination, increasing government support, increasing demand for pediatric multivalent vaccines, increasing funding for vaccine research, and rising demand for multivalent vaccines.

The multivalent vaccines market size is expected to see strong growth in the next few years. It will grow to $13.32 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to the rising incidence of infectious illnesses, increasing numbers of geriatric population, increasing government and private sector investment, growing focus on vaccine safety and effectiveness, and growing focus on therapeutic vaccines. Major trends in the forecast period include greater emphasis on combination vaccines, integration of digital health technologies, development in mRNA technology, development of personalized vaccines, and increase in research activities.

The increasing prevalence of infectious diseases is projected to significantly drive the growth of the multivalent vaccines market in the near future. Infectious diseases are caused by pathogens such as bacteria, viruses, fungi, or parasites, which can be transmitted through direct contact or contaminated surfaces, air, or water, varying in severity from mild to severe. The global travel landscape facilitates the rapid spread of these diseases, allowing pathogens to easily cross borders and infect new populations. Multivalent vaccines offer broader protection against infectious diseases by targeting multiple pathogen strains in a single dose, reducing the necessity for multiple shots. This comprehensive coverage enhances herd immunity and decreases disease prevalence, thereby improving public health outcomes. For example, a report released by TravelHealthPro in April 2024 noted that the UK reported 2,004 malaria cases in 2023, an increase from the 1,369 imported cases in 2022. As a result, the rising incidences of infectious diseases are a key factor driving the growth of the multivalent vaccines market.

Leading companies in the multivalent vaccines sector are concentrating on the development of advanced pentavalent vaccines to enhance overall public health outcomes by providing wider protection in a single dose. A pentavalent vaccine is specifically designed to safeguard against five distinct pathogens or strains. This consolidation of protections simplifies immunization schedules and improves overall vaccine coverage. For instance, in December 2023, Panacea Biotec Ltd., an India-based biotechnology firm, introduced EasyFourPol, the world's first fully liquid vaccine. This innovative vaccine protects against five serious diseases, including diphtheria, tetanus, pertussis, polio, and invasive infections from Haemophilus influenzae Type B. By eliminating the need for preparation by healthcare professionals, this ready-to-use combination vaccine streamlines the vaccination process. It offers equivalent protection to single-antigen vaccines, reduces the number of clinic visits required for children, and lowers overall immunization costs. Moreover, it enhances vaccination efficiency and minimizes environmental impact by decreasing the requirement for vials, syringes, and packaging.

In February 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Icosavax Inc. for $1.1 billion. This acquisition allows AstraZeneca to strengthen its late-stage pipeline with IVX-A12, enhancing its presence in the RSV vaccine market. The deal also incorporates Icosavax's expertise in protein design and virus-like particles (VLP), providing a foundation for developing additional multivalent vaccines targeting respiratory viruses. Icosavax Inc. is a US-based biotechnology company specializing in the creation of multivalent vaccines utilizing a protein virus-like particle (VLP) platform.

Major companies operating in the multivalent vaccines market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Moderna Inc., BioNTech SE, Zydus Lifesciences Limited, CSL Seqirus, Sinovac Biotech Ltd., GC Biopharma corp., Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Indian Immunologicals Ltd., Bavarian Nordic, Panacea Biotec Ltd., WestVac Biopharma Co. Ltd., VBI Vaccines Inc.

North America was the largest region in the multivalent vaccines market in 2023. The regions covered in the multivalent vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the multivalent vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The multivalent vaccines market consists of sales of bivalent vaccines, trivalent vaccines, and polyvalent vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Multivalent Vaccines Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on multivalent vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for multivalent vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The multivalent vaccines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Conjugate Vaccines; Inactivated And Subunit Vaccines; Live Attenuated Vaccines; Toxoid Vaccines; Recombinant Vaccines
• 2) By Disease: Influenza; Pneumonia; Hepatitis; Meningitis; Rotavirus
• 3) By Route Of Administration: Oral; Injectable
• 4) By Age Group: Pediatrics; Adults; Geriatrics
• 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Conjugate Vaccines: Polysaccharide Conjugate Vaccines; Protein Conjugate Vaccines
• 2) By Inactivated And Subunit Vaccines: Inactivated Whole Virus Vaccines; Subunit Protein Vaccines; Virus-Like Particle Vaccines
• 3) By Live Attenuated Vaccines: Live Attenuated Bacterial Vaccines; Live Attenuated Viral Vaccines
• 4) By Toxoid Vaccines: Diphtheria Toxoid Vaccines; Tetanus Toxoid Vaccines
• 5) By Recombinant Vaccines: Recombinant Protein Vaccines; Recombinant DNA Vaccines
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Sanofi SA; AstraZeneca plc; Abbott Laboratories
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Multivalent Vaccines Market Characteristics

3. Multivalent Vaccines Market Trends And Strategies

4. Multivalent Vaccines Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Multivalent Vaccines Growth Analysis And Strategic Analysis Framework

• 5.1. Global Multivalent Vaccines PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Multivalent Vaccines Market Growth Rate Analysis
• 5.4. Global Multivalent Vaccines Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Multivalent Vaccines Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Multivalent Vaccines Total Addressable Market (TAM)

6. Multivalent Vaccines Market Segmentation

• 6.1. Global Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Conjugate Vaccines
• Inactivated And Subunit Vaccines
• Live Attenuated Vaccines
• Toxoid Vaccines
• Recombinant Vaccines
• 6.2. Global Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Influenza
• Pneumonia
• Hepatitis
• Meningitis
• Rotavirus
• 6.3. Global Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• 6.4. Global Multivalent Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatrics
• Adults
• Geriatrics
• 6.5. Global Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.6. Global Multivalent Vaccines Market, Sub-Segmentation Of Conjugate Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Polysaccharide Conjugate Vaccines
• Protein Conjugate Vaccines
• 6.7. Global Multivalent Vaccines Market, Sub-Segmentation Of Inactivated And Subunit Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inactivated Whole Virus Vaccines
• Subunit Protein Vaccines
• Virus-Like Particle Vaccines
• 6.8. Global Multivalent Vaccines Market, Sub-Segmentation Of Live Attenuated Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Live Attenuated Bacterial Vaccines
• Live Attenuated Viral Vaccines
• 6.9. Global Multivalent Vaccines Market, Sub-Segmentation Of Toxoid Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diphtheria Toxoid Vaccines
• Tetanus Toxoid Vaccines
• 6.10. Global Multivalent Vaccines Market, Sub-Segmentation Of Recombinant Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Protein Vaccines
• Recombinant DNA Vaccines

7. Multivalent Vaccines Market Regional And Country Analysis

• 7.1. Global Multivalent Vaccines Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Multivalent Vaccines Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Multivalent Vaccines Market

• 8.1. Asia-Pacific Multivalent Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Multivalent Vaccines Market

• 9.1. China Multivalent Vaccines Market Overview
• 9.2. China Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Multivalent Vaccines Market

• 10.1. India Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Multivalent Vaccines Market

• 11.1. Japan Multivalent Vaccines Market Overview
• 11.2. Japan Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Multivalent Vaccines Market

• 12.1. Australia Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Multivalent Vaccines Market

• 13.1. Indonesia Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Multivalent Vaccines Market

• 14.1. South Korea Multivalent Vaccines Market Overview
• 14.2. South Korea Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Multivalent Vaccines Market

• 15.1. Western Europe Multivalent Vaccines Market Overview
• 15.2. Western Europe Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Multivalent Vaccines Market

• 16.1. UK Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Multivalent Vaccines Market

• 17.1. Germany Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Multivalent Vaccines Market

• 18.1. France Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Multivalent Vaccines Market

• 19.1. Italy Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Multivalent Vaccines Market

• 20.1. Spain Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Multivalent Vaccines Market

• 21.1. Eastern Europe Multivalent Vaccines Market Overview
• 21.2. Eastern Europe Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Multivalent Vaccines Market

• 22.1. Russia Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Multivalent Vaccines Market

• 23.1. North America Multivalent Vaccines Market Overview
• 23.2. North America Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Multivalent Vaccines Market

• 24.1. USA Multivalent Vaccines Market Overview
• 24.2. USA Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Multivalent Vaccines Market

• 25.1. Canada Multivalent Vaccines Market Overview
• 25.2. Canada Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Multivalent Vaccines Market

• 26.1. South America Multivalent Vaccines Market Overview
• 26.2. South America Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Multivalent Vaccines Market

• 27.1. Brazil Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Multivalent Vaccines Market

• 28.1. Middle East Multivalent Vaccines Market Overview
• 28.2. Middle East Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Multivalent Vaccines Market

• 29.1. Africa Multivalent Vaccines Market Overview
• 29.2. Africa Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Multivalent Vaccines Market Competitive Landscape And Company Profiles

• 30.1. Multivalent Vaccines Market Competitive Landscape
• 30.2. Multivalent Vaccines Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

31. Multivalent Vaccines Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. GlaxoSmithKline plc
• 31.3. Boehringer Ingelheim International GmbH
• 31.4. Moderna Inc.
• 31.5. BioNTech SE
• 31.6. Zydus Lifesciences Limited
• 31.7. CSL Seqirus
• 31.8. Sinovac Biotech Ltd.
• 31.9. GC Biopharma corp.
• 31.10. Emergent BioSolutions Inc.
• 31.11. Serum Institute of India Pvt. Ltd.
• 31.12. Indian Immunologicals Ltd.
• 31.13. Bavarian Nordic
• 31.14. Panacea Biotec Ltd.
• 31.15. WestVac Biopharma Co. Ltd.

32. Global Multivalent Vaccines Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Multivalent Vaccines Market

34. Recent Developments In The Multivalent Vaccines Market

35. Multivalent Vaccines Market High Potential Countries, Segments and Strategies

• 35.1 Multivalent Vaccines Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Multivalent Vaccines Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Multivalent Vaccines Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer